Brexanolone, a First-In-Class Neurosteroid Medication: Mechanism of Action, Clinical, and Translational Science.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacology and clinical trials with no new human data or systematic synthesis.
PubMed 42563143 · doi:10.1111/cts.70671
What was done
This narrative review summarizes translational, pharmacological, and clinical data regarding brexanolone, an intravenous formulation of allopregnanolone and positive allosteric modulator of GABA_A receptors approved for the treatment of postpartum depression (PPD).
What was found
The abstract reports no primary statistical numbers or effect sizes. It notes that a 60-hour continuous intravenous infusion of brexanolone leads to significant reductions in depressive symptoms by the end of the infusion, with improvements maintained through 30 days of follow-up. Metabolism occurs through non-CYP pathways (keto-reduction, glucuronidation, sulfation), requiring no dose adjustment for eGFR 15–89 mL/min/1.73 m², but should be avoided in end-stage renal disease (eGFR < 15 mL/min/1.73 m²) due to vehicle accumulation (betadex sulfobutyl ether sodium). Clinical use is restricted by mandatory Risk Evaluation and Mitigation Strategy (REMS) enrollment due to risks of sudden loss of consciousness and excessive sedation.
Why it matters
Brexanolone represents a fast-acting, neurosteroid-based mechanism for postpartum depression that acts within hours rather than weeks. However, clinical implementation is constrained by the necessity of a 60-hour continuous intravenous infusion and inpatient safety monitoring.
Limits
As a narrative review, the paper presents no new experimental data or systematic meta-analysis. The abstract provides no quantitative effect estimates or sample sizes.
Cited by
- supports Allopregnanolone binds to GABA receptors in the brain.